文献速递产科母胎医学

妊娠期COVID-19与子痫前期:INTERCOVID前瞻性纵向研究结果

Preeclampsia and COVID-19: results from the INTERCOVID prospective longitudinal study.
PubMed 文献 · Am J Obstet Gynecol · 2021-06-26

这项在18国43家机构开展的前瞻性纵向观察研究纳入2184名孕妇,发现妊娠期COVID-19与子痫前期存在独立关联(调整后RR 1.77,95%CI 1.25-2.52),初产妇中更显著(RR 1.89,95%CI 1.17-3.05)。两种疾病并存时早产及不良围产结局风险呈阶梯式增加。

要点

  • 妊娠期COVID-19与子痫前期独立相关,初产妇风险更高。
  • COVID-19合并子痫前期者早产及不良围产结局风险显著增加。
  • 子痫前期孕妇应视为COVID-19高危人群。

核心结论

  • 妊娠期COVID-19与子痫前期强烈相关,尤其在初产妇中,且独立于已知风险因素和基础疾病。
  • COVID-19严重程度似乎不是该关联的影响因素。
  • 两种疾病独立且叠加地增加早产、严重围产期发病和死亡及不良产妇结局风险。

研究设计与样本

  • 多中心前瞻性纵向观察性研究,采用诊断与未诊断不匹配设计。
  • 共纳入2184名孕妇,其中COVID-19诊断组725名(33.2%),未诊断组1459名(66.8%)。
  • 来自18个国家43家机构,使用INTERGROWTH-21st标准化方案随访至出院。

主要发现

  • 子痫前期总体发生123例,COVID-19诊断组59/725(8.1%),未诊断组64/1459(4.4%),风险比1.86(95%CI 1.32-2.61)。
  • 调整社会人口学因素及共同相关疾病后,所有女性子痫前期风险比1.77(95%CI 1.25-2.52),初产妇1.89(95%CI 1.17-3.05),经产妇1.64(95%CI 0.99-2.73)无统计学显著性。
  • COVID-19合并子痫前期者早产风险比:所有女性4.05(95%CI 2.99-5.49),初产妇6.26(95%CI 4.35-9.00)。
  • 与无任何疾病者相比,复合不良围产结局风险比呈阶梯式增加:单纯COVID-19为2.16(95%CI 1.63-2.86),单纯子痫前期为2.53(95%CI 1.44-4.45),两者并存为2.84(95%CI 1.67-4.82)。
  • 复合不良产妇结局风险比分别为1.76(95%CI 1.32-2.35)、2.07(95%CI 1.20-3.57)和2.77(95%CI 1.66-4.63)。

临床怎么用

  • 对妊娠期COVID-19患者应警惕子痫前期发生,尤其初产妇。
  • 子痫前期孕妇应视为COVID-19特别脆弱群体,加强防护和监测。
  • 两种疾病并存时需强化围产期管理以降低早产和不良结局风险。

局限性

  • 观察性设计无法完全排除残余混杂。
  • COVID-19严重程度与子痫前期关联的分析可能受样本量限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is unclear whether the suggested link between COVID-19 during pregnancy and preeclampsia is an independent association or if these are caused by common risk factors. OBJECTIVE: This study aimed to quantify any independent association between COVID-19 during pregnancy and preeclampsia and to determine the effect of these variables on maternal and neonatal morbidity and mortality. STUDY DESIGN: This was a large, longitudinal, prospective, unmatched diagnosed and not-diagnosed observational study assessing the effect of COVID-19 during pregnancy on mothers and neonates. Two consecutive not-diagnosed women were concomitantly enrolled immediately after each diagnosed woman was identified, at any stage during pregnancy or delivery, and at the same level of care to minimize bias. Women and neonates were followed until hospital discharge using the standardized INTERGROWTH-21st protocols and electronic data management system. A total of 43 institutions in 18 countries contributed to the study sample. The independent association between the 2 entities was quantified with the risk factors known to be associated with preeclampsia analyzed in each group. The outcomes were compared among women with COVID-19 alone, preeclampsia alone, both conditions, and those without either of the 2 conditions. RESULTS: We enrolled 2184 pregnant women; of these, 725 (33.2%) were enrolled in the COVID-19 diagnosed and 1459 (66.8%) in the COVID-19 not-diagnosed groups. Of these women, 123 had preeclampsia of which 59 of 725 (8.1%) were in the COVID-19 diagnosed group and 64 of 1459 (4.4%) were in the not-diagnosed group (risk ratio, 1.86; 95% confidence interval, 1.32-2.61). After adjustment for sociodemographic factors and conditions associated with both COVID-19 and preeclampsia, the risk ratio for preeclampsia remained significant among all women (risk ratio, 1.77; 95% confidence interval, 1.25-2.52) and nulliparous women specifically (risk ratio, 1.89; 95% confidence interval, 1.17-3.05). There was a trend but no statistical significance among parous women (risk ratio, 1.64; 95% confidence interval, 0.99-2.73). The risk ratio for preterm birth for all women diagnosed with COVID-19 and preeclampsia was 4.05 (95% confidence interval, 2.99-5.49) and 6.26 (95% confidence interval, 4.35-9.00) for nulliparous women. Compared with women with neither condition diagnosed, the composite adverse perinatal outcome showed a stepwise increase in the risk ratio for COVID-19 without preeclampsia, preeclampsia without COVID-19, and COVID-19 with preeclampsia (risk ratio, 2.16; 95% confidence interval, 1.63-2.86; risk ratio, 2.53; 95% confidence interval, 1.44-4.45; and risk ratio, 2.84; 95% confidence interval, 1.67-4.82, respectively). Similar findings were found for the composite adverse maternal outcome with risk ratios of 1.76 (95% confidence interval, 1.32-2.35), 2.07 (95% confidence interval, 1.20-3.57), and 2.77 (95% confidence interval, 1.66-4.63). The association between COVID-19 and gestational hypertension and the direction of the effects on preterm birth and adverse perinatal and maternal outcomes, were similar to preeclampsia, but confined to nulliparous women with lower risk ratios. CONCLUSION: COVID-19 during pregnancy is strongly associated with preeclampsia, especially among nulliparous women. This association is independent of any risk factors and preexisting conditions. COVID-19 severity does not seem to be a factor in this association. Both conditions are associated independently of and in an additive fashion with preterm birth, severe perinatal morbidity and mortality, and adverse maternal outcomes. Women with preeclampsia should be considered a particularly vulnerable group with regard to the risks posed by COVID-19.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Papageorghiou AT, Deruelle P, Gunier RB, et al. Preeclampsia and COVID-19: results from the INTERCOVID prospective longitudinal study. Am J Obstet Gynecol. 2021. PMID: 34187688. doi:10.1016/j.ajog.2021.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。